Phase II Study: Stereotactic Ablative Radiotherapy for Renal Tumors
Condition: Renal Tumor
Study Type: Interventional
Clinical Trials Identifier NCT 8-digits: NCT03747133
Sponsor: University Health Network, Toronto
Eligibility:
- Age: minimum 18 Years maximum N/A
- Gender: All
Inclusion Criteria:
- Solid Kidney Mass (primary RCC or metastasis) amenable to SABR ≤6cm
- Histological or radiological diagnosis of renal tumor
- Inoperable: High risk for surgery or declined surgery
- ECOG performance status of 0-3
Exclusion Criteria:
- ≥5 active metastases
- Sysstemic therapy (except endocrine therapy) wthin 6 days prior to SABR
- Prior abdominal radiotherapy with fields overlap resulting in excessive doses to the involved kidney
- Patients with end stage renal failure > 4(KDOQI guidelines)
- Familial Syndrome: Von Hippel-Lindau disease, Polycystic Kidney Disease, Hereditary Papillary RCC or Tuber Sclerosis
View trial on ClinicalTrials.gov